Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer
July 5th 2023Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.
Read More